Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study
Toni K. Choueiri, Laurence Albigès(Institut Gustave Roussy), Philippe Barthélémy(Institut de Cancérologie Strasbourg), Roberto Iacovelli(Università Cattolica del Sacro Cuore), Sheik Emambux(Centre Hospitalier Universitaire de Poitiers), Javier Molina‐Cerrillo(Hospital Universitario Ramón y Cajal), Benjamin Garmezy(Sarah Cannon), Pedro C. Barata, Arnab Basu(University of Alabama at Birmingham), María T. Bourlon(Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán), Helen Moon(Kaiser Permanente Riverside Medical Center), Raffaele Ratta(Hôpital Foch), Rana R. McKay(University of California, San Diego), Alex Chehrazi‐Raffle(City of Hope), Hans J. Hammers(The University of Texas Southwestern Medical Center), Daniel Y.C. Heng, Edgar Braendle(AVEO Oncology (United States)), Kathryn E. Beckermann(Vanderbilt University Medical Center), Bradley A. McGregor(Dana-Farber Cancer Institute), Robert J. Motzer(Memorial Sloan Kettering Cancer Center)
Cited by 67Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis